HomeBupropion

Bupropion

Also known as: Bupropion

Route: Oral

Check Bupropion Interactions →
52 interactions on record⛔ Black Box Warning

Bupropion has 52 known drug interactions based on U.S. FDA drug labeling data. 17 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acetaminophen And Codeine Phosphate, Amantadine, Cyclobenzaprine. Patients taking Bupropion should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
52
Major
17
Moderate
34

Major (17)

Moderate (34)

  • Bupropion + CarbamazepineCYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm
  • Bupropion + ClopidogrelCYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.
  • Bupropion + ClozapineCYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose r
  • Bupropion + DesipramineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases desipramine concentrations; consider dose reduction.
  • Bupropion + EfavirenzCYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend
  • Bupropion + FexinidazoleFexinidazole induces CYP2B6, decreasing bupropion plasma concentrations and efficacy.
  • Bupropion + FlecainideCYP2D6 substrate; bupropion inhibits CYP2D6 and increases flecainide concentrations; consider dose reduction.
  • Bupropion + FluoxetineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases fluoxetine concentrations; consider dose reduction.
  • Bupropion + HaloperidolCYP2D6 substrate; bupropion inhibits CYP2D6 and increases haloperidol concentrations; consider dose reduction.
  • Bupropion + ImipramineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases imipramine concentrations; consider dose reduction.
  • Bupropion + Ioflupane I-123Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.
  • Bupropion + Isavuconazonium SulfateConcomitant administration with CRESEMBA requires caution.
  • Bupropion + LemborexantCYP2B6 substrate whose AUC is decreased by lemborexant, potentially reducing efficacy. Monitor for adequate clinical res
  • Bupropion + LopinavirCYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend
  • Bupropion + MetoprololPotent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.
  • Bupropion + Metoprolol TartratePotent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.
  • Bupropion + Metoprolol Tartrate And HydrochlorothiazidePotent CYP2D6 inhibitor may increase plasma concentration of metoprolol; caution should be exercised.
  • Bupropion + MifepristoneMifepristone should be used with caution with bupropion; metabolized by CYP2B6.
  • Bupropion + NortriptylineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases nortriptyline concentrations; consider dose reduction.
  • Bupropion + OliceridineCYP2D6 inhibitor that increases oliceridine plasma concentration, resulting in increased or prolonged opioid effects. Ma
  • Bupropion + ParoxetineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases paroxetine concentrations; consider dose reduction.
  • Bupropion + PhenobarbitalCYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm
  • Bupropion + PhenytoinCYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm
  • Bupropion + PropafenoneCYP2D6 substrate; bupropion inhibits CYP2D6 and increases propafenone concentrations; consider dose reduction.
  • Bupropion + Propranolol HydrochlorideCYP2D6 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.
  • Bupropion + RisperidoneCYP2D6 substrate; bupropion inhibits CYP2D6 and increases risperidone concentrations; consider dose reduction.
  • Bupropion + RitonavirCYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend
  • Bupropion + SertralineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases sertraline concentrations; consider dose reduction.
  • Bupropion + Telotristat EthylTelotristat ethyl may decrease the efficacy of bupropion by decreasing its systemic exposure. Monitor patient response a
  • Bupropion + ThioridazineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases thioridazine concentrations; consider dose reduction.
  • Bupropion + TiclopidineCYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.
  • Bupropion + Varenicline TartrateVarenicline did not alter bupropion pharmacokinetics, but safety of combination has not been established. Use with cauti
  • Bupropion + VenlafaxineCYP2D6 substrate; bupropion inhibits CYP2D6 and increases venlafaxine concentrations; consider dose reduction.
  • Bupropion + VortioxetineStrong CYP2D6 inhibitor increases plasma concentrations of vortioxetine. Reduce TRINTELLIX dose by half when coadministe

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.